ArticleDiscover nano2024
Performance of Ag-doped CuO nanoparticles for photocatalytic activity applications: Synthesis, characterization, and antimicrobial activity.
Article in Discover nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Fabrication of novel nitrogen-doped δ-AlNanoscale advances · 2026Article
- Synthesis and characterization of Ag doped CuO nanorods electrode for non-enzymatic glucose sensing.Scientific reports · 2026Article
- Sustainable synthesis and photocatalytic insights into Ag-doped copper oxide nanoparticles: a comparative study.Scientific reports · 2026Article
- Silver doped copper oxide decorated graphene oxide nanocomposite for electrochemical sensing, photocatalysis and biomedical applications.RSC advances · 2025Article
- Facile preparation of FeRSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The auto-combustion method synthesized CuO NPs and Ag/CuO NPs. The Ag/CuO NPs were analyzed using Fourier-transform infrared, X-ray diffraction, scanning electron microscope, and Energy-dispersive X-ray spectroscopy instrumental analyses. The energy band gap, as determined by DRS properties, decreases from 3.82 to 3.50 eV for pure CuO and 10% Ag/CuO NPs, respectively. The photodegradation efficiency of Rhodamine-B & Carmine by 10% Ag/CuO NPs was nearly 98.9 and 97.8%, respectively. Antimicrobial trials revealed that the antimicrobial efficacy of Ag/CuO NPs at several dosages (20, 40, 60, 80, 100, and 120 µg/mL) against human pathogens was initially assessed using the agar well-diffusion method, and then the broth dilution method. Noticeably, the minimum inhibitory concentration of Ag/CuO NPs for all pathogens ranged from 100 to 120 µg/ml, was determined. Generally, the observed minimum microbicide concentration has a wide range of Ag/CuO NPs doses, ranging from 150 to 300 µg/ml, which helps kill (99.99%) all tested pathogenic cells. The largest relative inhibitory activities (%) were recorded against Escherichia coli (81.45 ± 1.39) at 120 g/mL of Ag/CuO NPs and 100 μg/mL (80.43 ± 0.59), followed by 80 µg/mL (72.33 ± 0.82). Additionally, the lowest relative inhibitory activities (%) were monitored versus fungal cells and Gram-positive bacteria at 120 µg/mL of Ag/CuO NPs as 52.17 ± 1.49 and 53.42 ± 1.71; respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.